Biocon reports 17% drop in net profit, Christiane Hamacher steps down as MD of Biocon Biologics

“2020 has been one of the most challenging years for the world with an unprecedented pandemic impact on the global economy. We continue to face headwinds across operational, regulatory and commercial functions which have been deterrents to our planned market expansion. However, we expect normalization by next fiscal,” said Kiran Mazumdar-Shaw, executive chairperson, Biocon.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3c09Qyw
via IFTTT